Skip to content
lifestyle.duovoltart.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
BioVie, Inc.
BioVie Updates Parkinson’s Phase 3 Program, FDA Engagement
September 8, 2026
BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
August 31, 2026
BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease
August 6, 2026
Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2
May 27, 2026
BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
May 26, 2026
←
Previous Page
1
2